Navigation Links
Sequenom to Host Analyst Day on Monday, November 14, 2011
Date:11/14/2011

SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it will host an Investor and Analyst Day at NASDAQ Tower in New York on Monday, November 14, 2011 from 2:00 to 5:00 pm ET. Key members of the company's management team will offer an in-depth discussion of the business, specifically focusing on the recent commercial launch of the MaterniT21 laboratory developed test (LDT).

Space for the event is limited and, therefore, by invitation only.  For those who cannot attend, the presentation will be web cast live through the "Investor Relations" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast. 

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
4. Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
5. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
6. Sequenom Enters Into New $30.0 Million Credit Facility
7. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
8. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
9. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... results of a new study led by George ... evidence that nucleation of ice in small droplets ... water,s behavior at the nanoscale. The formation of ... scientific research question whose answer also has important ... , The crystallization of ice from supercooled water ...
(Date:5/21/2013)... The congress of the ERA-EDTA (European Renal Association ... congress in Europe on nephrology ... Istanbul to share their knowledge ... have been presented: / (1) Gupta, A ... REDUCES ESA USE" By SFP-iron administration, the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5
... Nets to Prevent Serious Health Hazards ... Associated with Diethylene ... Pharmacopeial (USP),Convention today announced a revised Glycerin monograph in ... United States. The,revision strengthens safety nets to prevent serious ...
... The following was issued,today by the Greater Baltimore ... CEO, Greater Baltimore Committee, 140 company owners, executives ... The third annual Greater Baltimore Region Bioscience Awards, ... / Breakfast & Registration, 8:45 - 9:30 a.m. ...
... March 17 Mercury Therapeutics,Inc. (MTI), a ... protein,kinase targeted drugs, announces that it has ... advise on its strategic and partnering,opportunities, with ... shareholders., This appointment follows a significant ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:5/21/2013)... MA -- Over the past few decades, scientists have ... angioplasty balloons and metallic stents. While generally effective, each ... side effects. , A new study from MIT analyzes ... the benefits of angioplasty balloons and drug-releasing stents, but ... balloon is inflated in the artery for only a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
(Date:5/20/2013)... (NSF) planning grant will help establish the Center for ... the University of Illinois at Urbana-Champaign and Worcester Polytechnic ... devoted to research in drying moist, porous materials such ... products; chemical products; textiles; and biopharmaceuticals," said Hao Feng, ... human nutrition and the Illinois site director. , According ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... forest loss accounts for an estimated 17% of global ... to reduce these greenhouse gas fluxes to the atmosphere, ... is working to adopt a strategy for Reducing Emissions ... climate treaty. For tropical nations to be effective ...
... keeping a secret that may be the key to defeating ... at Rice University and Baylor College of Medicine (BCM) have ... for evading detection by the immune system. Comparing its ... first known appearance in the deadly "Spanish flu" outbreak of ...
... (Dec. 10, 2009) -- One of the promises of nanomedicine ... on diseased cells and get inside them. Nanoparticles can carry ... diagnostic tests; and they may eventually even enter a cell,s ... much luck as engineering. "Everything in nanomedicine right now ...
Cached Biology News:First phase of pan-tropical forest mapping debuting at COP15 2First phase of pan-tropical forest mapping debuting at COP15 3Study reveals H1N1 unexpected weakness 2Nanomedicine: Ending 'hit and miss' design 2Nanomedicine: Ending 'hit and miss' design 3
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Biology Products: